The FDA has designated miltefosine as an orphan drug for the treatment of Acanthamoeba keratitis, according to a press release from Profunda.Impavido (miltefosine) was licensed by Profunda from Knight Therapeutics in 2015.
LENSARĀ® Strategic Restructure in Partnership with PDL BioPharma, Inc.
ORLANDO, Fla.–(BUSINESS WIRE)–LENSAR announced the filing of Chapter 11 bankruptcy and its strategic restructuring in partnership with PDL BioPharma to reduce debt and strengthen the future growth of the platform & balance sheet.
LASIK and Dry Eyes: What’s the Connection?
LASIK is a popular way of correcting vision, but complications can include dry eyes. Learn more about LASIK, dry eyes, and other vision correction options.
VIDEO: Vitreoretinal surgeons benefit from digital 3-D assisted surgery
Digital 3-D imaging is becoming more useful in vitreoretinal surgery, Jorge A. Fortun, MD, said at the OSN New York meeting. As technology continues to improve, Fortun believes that 3-D digital imaging will allow surgeons to move from optical microscop…
Aerie Pharmaceuticals Announces Appointment of Judith J. Robertson as Chief Commercial Officer
IRVINE, Calif.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases…
CMS expands opportunities under the Quality Payment Program
CMS is offering clinicians additional opportunities to join Advanced Alternative Payment Models under the Quality Payment Program within MACRA to enhance care and earn additional incentive payments.“The CMS Innovation Center, which the Affordable Care Act created, takes best practices from physicians and other clinicians and promotes them across the nation,” Andy Slavitt, acting administrator of CMS, said in a news release. “Thanks to the bipartisan MACRA, more clinicians and their patients will benefit from being a part of these models. That’s good for the future of Medicare, the health of (Read more...)